http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105727305-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-64 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-704 |
| filingDate | 2016-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-09-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105727305-B |
| titleOfInvention | A kind of Legumain response release adriamycin slow release nanometer formulation and preparation method with as the application for preparing carrier medicament |
| abstract | A kind of Legumain response release adriamycin slow release nanometer formulation and preparation method with as the application for preparing carrier medicament, the present invention expresses the biological characteristics of Legumain using tumor tissues height, the nano-hydrogel for preparing Legumain responses, to realize the dual-target effect to tumor tissues（Active targeting and passive target）Reduce the secondary injury of adriamycin normal tissue, the present invention is using hyaluronic acid as the basic material of adriamycin pharmaceutical carrier, hyaluronic acid is widely present in the normal structure with organism, other opposite exogenous materials, have higher biocompatibility and safety, the also high expression hyaluronic acid receptor of tumor tissues, therefore using hyaluronic acid as carrier material, moreover it is possible to further achieve the effect that targeting. |
| priorityDate | 2016-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 48.